AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26319220 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG)
Number of subjects: 131
Study 26319220 — intervention group
Group type: COMPARATOR
Intervention: PEG
Number of subjects: 131
Study 25505230 — intervention group
Group type: EXPERIMENTAL
Intervention: POLE-mutant ECs
Number of subjects: 788
Study 25505230 — intervention group
Group type: EXPERIMENTAL
Intervention: POLE-mutant ECs (grade 3 tumors)
Number of subjects: 788
Study 25505230 — intervention group
Group type: EXPERIMENTAL
Intervention: POLE-mutant ECs (from additional series)
Number of subjects: 788
Study 24713545 — intervention group
Group type: EXPERIMENTAL
Intervention: AEZS-108 (267mg/m², equimolar to 76.8mg/m² of free doxorubicin) every 3 weeks as a two-hour i.v. infusion
Number of subjects: 42
Study 22167127 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 528
Study 22167127 — intervention group
Group type: EXPERIMENTAL
Intervention: Breaks in sedentary time (BST)
Number of subjects: 528
Study 22167127 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of sedentary time at baseline
Number of subjects: 528
Study 22167127 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BST
Number of subjects: 528
Study 20151839 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (300 mg once or twice daily) with zidovudine-lamivudine
Number of subjects: 721
Study 20151839 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (600 mg once daily) with zidovudine-lamivudine
Number of subjects: 721
Study 20151839 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (300 mg once or twice daily)
Number of subjects: 721
Study 20151839 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (600 mg once daily)
Number of subjects: 721
Study 18628619 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care model (IC)
Number of subjects: 186
Study 18628619 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 186
Study 15896918 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg dexamethasone suppression test (DST) in BPD patients with comorbid PTSD
Number of subjects: 21
Study 15896918 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg dexamethasone suppression test (DST) in total BPD group
Number of subjects: 21
Study 15896918 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg dexamethasone suppression test (DST) in healthy controls
Number of subjects: 21
Study 15896918 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg dexamethasone suppression test (DST) in BPD patients without PTSD
Number of subjects: 21
Study 11941237 — intervention group
Group type: EXPERIMENTAL
Intervention: Greenbaum's method (subtenon anesthesia using a flexible plastic cannula)
Number of subjects: 80
Study 11941237 — intervention group
Group type: COMPARATOR
Intervention: Ripart's method (subtenon anesthesia using a 23G hypodermic needle)
Number of subjects: 80
Study 11941237 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods (Greenbaum's and Ripart's)
Number of subjects: 80
Study 10066854 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional treatment by a qualified physiotherapist
Number of subjects: 282
Study 10066854 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional treatment by a physiotherapy assistant
Number of subjects: 282
Study 10066854 — intervention group
Group type: COMPARATOR
Intervention: Routine physiotherapy
Number of subjects: 282
Study 8828605 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary restriction of phenylalanine (continued therapy)
Number of subjects: 0
Study 8828605 — intervention group
Group type: COMPARATOR
Intervention: Dietary restriction of phenylalanine (discontinued therapy)
Number of subjects: 0
Study 8828605 — intervention group
Group type: EXPERIMENTAL
Intervention: Bender Gestalt test
Number of subjects: 0
Study 1564674 — intervention group
Group type: EXPERIMENTAL
Intervention: Future oriented hypnotic imagery presented as hypnosis
Number of subjects: 0
Study 1564674 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training
Number of subjects: 0
Study 1564674 — intervention group
Group type: EXPERIMENTAL
Intervention: Future oriented hypnotic imagery not presented as hypnosis
Number of subjects: 0
Study 3932499 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% cromolyn sodium (CS) ophthalmic solution, used six times daily for 5 weeks
Number of subjects: 58
Study 3932499 — intervention group
Group type: COMPARATOR
Intervention: Placebo, used six times daily for 5 weeks
Number of subjects: 58
Study 31701389 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat-related beliefs
Number of subjects: 248
Study 31701389 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective beliefs
Number of subjects: 248
Study 29543938 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE plus RT (maximum 45 Gy with fraction size of 2.5 to 3 Gy, every 6 weeks)
Number of subjects: 90
Study 29543938 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE plus RT
Number of subjects: 90
Study 29543938 — intervention group
Group type: COMPARATOR
Intervention: sorafenib (400 mg twice daily)
Number of subjects: 90
Study 29543938 — intervention group
Group type: COMPARATOR
Intervention: sorafenib
Number of subjects: 90
Study 26414976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBT-I)
Number of subjects: 113
Study 26414976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for pain
Number of subjects: 113
Study 26414976 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 113
Study 24646637 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin core build-up material, Gradia Core (Group 1A)
Number of subjects: 120
Study 24646637 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive universal cement GCem Automix (Group 2B)
Number of subjects: 120
Study 22389467 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 48
Study 19813008 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg oral salmon calcitonin (sCT) at 08:00
Number of subjects: 130
Study 19813008 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg oral salmon calcitonin (sCT) at 17:00
Number of subjects: 130
Study 19813008 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg oral salmon calcitonin (sCT) at 22:00
Number of subjects: 130
Study 19813008 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg oral salmon calcitonin (sCT) twice daily for 14 days at 08:00
Number of subjects: 130
Study 19813008 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg oral salmon calcitonin (sCT) twice daily for 14 days at 17:00
Number of subjects: 130
Study 19813008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 17624485 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation programme
Number of subjects: 183
Study 17624485 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 183
Study 16237691 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA‐ME (C2 monitoring)
Number of subjects: 39
Study 16237691 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (C0 monitoring)
Number of subjects: 39
Study 12389268 — intervention group
Group type: EXPERIMENTAL
Intervention: CHANGE intervention (Change Habits by Applying New Goals and Experiences); delivered through five small-group, nurse-led sessions during the last three weeks of CR and at one and two months following CR.
Number of subjects: 0
Study 9952151 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0% lidocaine
Number of subjects: 109
Study 9952151 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% lidocaine
Number of subjects: 109
Study 9952151 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine
Number of subjects: 109
Study 7749977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 1 mg
Number of subjects: 0
Study 7749977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 3 mg
Number of subjects: 0
Study 7749977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 0
Study 7749977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 30 mg
Number of subjects: 0
Study 7749977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1546142 — intervention group
Group type: EXPERIMENTAL
Intervention: moclobemide, 450 mg/j
Number of subjects: 46
Study 1546142 — intervention group
Group type: COMPARATOR
Intervention: viloxazine, 300 mg/j
Number of subjects: 46
Study 1546142 — intervention group
Group type: COMPARATOR
Intervention: maprotiline, 150 mg/j
Number of subjects: 46
Study 6375537 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (480 mg/day for 6 weeks)
Number of subjects: 6
Study 6375537 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (480 mg/day for 6 weeks)
Number of subjects: 6
Study 30898353 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk protein-enriched beverage (MPB)
Number of subjects: 20
Study 30898353 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric carbohydrate-enriched beverage (CB)
Number of subjects: 20
Study 29898171 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Auriculotherapy (G1)
Number of subjects: 168
Study 29898171 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo Auriculotherapy (G2)
Number of subjects: 168
Study 29898171 — intervention group
Group type: COMPARATOR
Intervention: Control (G3)
Number of subjects: 168
Study 27381308 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 0
Study 27381308 — intervention group
Group type: COMPARATOR
Intervention: Normal weight patients
Number of subjects: 0
Study 25216649 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS) with pre-relax condition (FDI relaxed)
Number of subjects: 36
Study 25216649 — intervention group
Group type: COMPARATOR
Intervention: Continuous theta burst stimulation (cTBS) with pre-active condition (10% of maximal voluntary contraction)
Number of subjects: 36
Study 22332827 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (NE) at 59 μmol/L
Number of subjects: 0
Study 22332827 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (VP) at 100 nmol/L
Number of subjects: 0
Study 20688574 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamins (2 mg folic acid, 25 mg vitamin B6, and 0.5 mg vitamin B12)
Number of subjects: 8164
Study 20688574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8164
Study 18044297 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (bupivacaine 0.25% 6-10 ml + fentanyl 50-100 microg, followed by bupivacaine 0.125% + fentanyl 1-2 microg/ml at 6-12 ml/h)
Number of subjects: 861
Study 18044297 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 861
Study 15642074 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional diet with agar
Number of subjects: 76
Study 15642074 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet
Number of subjects: 76
Study 11816327 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA), initial dose of 10-15 mg/kg given 10-15 minutes before tourniquet release, with possible repeat doses every 6-8 hours during the first postoperative day.
Number of subjects: 0
Study 11816327 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 0
Study 10094978 — intervention group
Group type: EXPERIMENTAL
Intervention: OMRI-Hep-B
Number of subjects: 15
Study 10094978 — intervention group
Group type: COMPARATOR
Intervention: Hepatect
Number of subjects: 15
Study 7755658 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous familial hypercholesterolaemia (FH)
Number of subjects: 12
Study 7755658 — intervention group
Group type: COMPARATOR
Intervention: Normocholesterolaemic subjects (Control)
Number of subjects: 12
Study 2148629 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigason alone
Number of subjects: 88
Study 2148629 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigason combined with PUVA
Number of subjects: 88
Study 2148629 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigason combined with SUP
Number of subjects: 88
Study 2148629 — intervention group
Group type: EXPERIMENTAL
Intervention: Roaccutan
Number of subjects: 88
Study 2148629 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoids (Tigason and Roaccutan)
Number of subjects: 88
Study 344914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephaloridine prophylaxis
Number of subjects: 139
Study 344914 — intervention group
Group type: COMPARATOR
Intervention: Placebo prophylaxis
Number of subjects: 139
Study 31162140 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP concentration (doubling) among white individuals
Number of subjects: 3610
Study 31162140 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP concentration (doubling) among black individuals
Number of subjects: 3610
Study 31162140 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP predictive ability across BMI and eGFR categories among white individuals
Number of subjects: 3610
Study 31162140 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP predictive ability among black individuals with obesity (BMI ≥ 30 kg/m2) or eGFR < 60 mL/min/1.73 m2
Number of subjects: 3610
Study 28738079 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (20 μg/ml)
Number of subjects: 98
Study 28738079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 25606478 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 60
Study 25606478 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 60
Study 23835693 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group (DCCT)
Number of subjects: 1441
Study 23835693 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment group (DCCT)
Number of subjects: 1441
Study 21245182 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/d)
Number of subjects: 205
Study 21245182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 19966532 — intervention group
Group type: EXPERIMENTAL
Intervention: Daikenchuto
Number of subjects: 14
Study 19966532 — intervention group
Group type: COMPARATOR
Intervention: Orengedokuto
Number of subjects: 14
Study 19966532 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 14
Study 17124698 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint modelling of repeated measurements and competing risks failure time data
Number of subjects: 0
Study 17124698 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint modelling approach
Number of subjects: 0
Study 17124698 — intervention group
Group type: EXPERIMENTAL
Intervention: EM-based algorithm for parameter estimates
Number of subjects: 0
Study 17124698 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation study
Number of subjects: 0
Study 15296554 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallstones diagnosed by ultrasound scan
Number of subjects: 75
Study 15296554 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients operated on for gallstone disease
Number of subjects: 75
Study 15296554 — intervention group
Group type: COMPARATOR
Intervention: Patients not operated on for gallstones
Number of subjects: 75
Study 15296554 — intervention group
Group type: COMPARATOR
Intervention: Patients without gallstones
Number of subjects: 75
Study 15296554 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 75
Study 11339520 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral suspension of meloxicam 7.5 mg daily
Number of subjects: 286
Study 11339520 — intervention group
Group type: COMPARATOR
Intervention: Solid formulation of meloxicam 15 mg
Number of subjects: 286
Study 9213408 — intervention group
Group type: EXPERIMENTAL
Intervention: Icelandic Moss (Cetraria islandica) lozenges, 0.48 g per day (10 lozenges per day)
Number of subjects: 61
Study 9213408 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 61
Study 7864949 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol delivered by metered-dose inhaler (MDI)
Number of subjects: 0
Study 7864949 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 0
Study 3666666 — intervention group
Group type: EXPERIMENTAL
Intervention: pirenzepine 50 mg b.i.d.
Number of subjects: 30
Study 3666666 — intervention group
Group type: COMPARATOR
Intervention: ranitidine 150 mg b.i.d.
Number of subjects: 30
Study 3666666 — intervention group
Group type: EXPERIMENTAL
Intervention: pirenzepine
Number of subjects: 30
Study 30224261 — intervention group
Group type: EXPERIMENTAL
Intervention: CHA2DS2‐VASc based anticoagulant treatment recommendation
Number of subjects: 2355
Study 30224261 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (reference practices)
Number of subjects: 2355
Study 28246005 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular-arterial coupling (Ea/Ees ratio)
Number of subjects: 234
Study 28246005 — intervention group
Group type: EXPERIMENTAL
Intervention: Load-independent contractility (Ees, PRSW)
Number of subjects: 234
Study 28246005 — intervention group
Group type: EXPERIMENTAL
Intervention: LV global longitudinal strain (GLS)
Number of subjects: 234
Study 28246005 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral E-wave over annular velocity E' ratio (E/E')
Number of subjects: 234
Study 28246005 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (EF)
Number of subjects: 234
Study 28246005 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification and regression analysis
Number of subjects: 234
Study 26374635 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric-focused training group (ETG)
Number of subjects: 26
Study 26374635 — intervention group
Group type: COMPARATOR
Intervention: Conventional training group (CTG)
Number of subjects: 26
Study 24284242 — intervention group
Group type: EXPERIMENTAL
Intervention: BMMCs with porous hydroxylapatite composite
Number of subjects: 35
Study 24284242 — intervention group
Group type: COMPARATOR
Intervention: Cell-free porous hydroxylapatite composite
Number of subjects: 35
Study 20553856 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated antenatal corticosteroid treatment
Number of subjects: 51
Study 20553856 — intervention group
Group type: COMPARATOR
Intervention: Single antenatal corticosteroid treatment
Number of subjects: 51
Study 19007589 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 mg
Number of subjects: 181
Study 19007589 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg
Number of subjects: 181
Study 19007589 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 60 mg
Number of subjects: 181
Study 19007589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 15728062 — intervention group
Group type: EXPERIMENTAL
Intervention: Impervious surgical drape
Number of subjects: 8
Study 15728062 — intervention group
Group type: COMPARATOR
Intervention: Large Surgical Drape
Number of subjects: 8
Study 15728062 — intervention group
Group type: COMPARATOR
Intervention: Medline Proxima
Number of subjects: 8
Study 15728062 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist skin
Number of subjects: 8
Study 12929196 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular caffeine injection (0.5 ml, 20 mM)
Number of subjects: 17
Study 10812530 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 1.0 mg per day
Number of subjects: 174
Study 10812530 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 5.0 mg per day
Number of subjects: 174
Study 10812530 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 174
Study 10812530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 8692301 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic CO2 laser vaporization treatment
Number of subjects: 46
Study 1519524 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina-directed medical therapy
Number of subjects: 600
Study 1519524 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina plus ambulatory electrocardiographic-directed medical therapy
Number of subjects: 600
Study 1519524 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 600
Study 1519524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 6234281 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg bd norfloxacin
Number of subjects: 122
Study 6234281 — intervention group
Group type: COMPARATOR
Intervention: 160/800 mg bd cotrimoxazole
Number of subjects: 122
Study 30777705 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise videogames
Number of subjects: 283
Study 30777705 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise
Number of subjects: 283
Study 30777705 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 283
Study 29633025 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-μg vaginal misoprostol, 3 hours prior to vaginoscopic hysteroscopy
Number of subjects: 122
Study 29633025 — intervention group
Group type: COMPARATOR
Intervention: No drug (control group)
Number of subjects: 122
Study 26541687 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (sertraline and mianserin)
Number of subjects: 280
Study 26541687 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible cognitive-behavioural therapy (CBT)
Number of subjects: 280
Study 26541687 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 280
Study 26541687 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of psychotherapy and medicine
Number of subjects: 280
Study 24637803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 27
Study 24637803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 22119063 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (20-40mg)
Number of subjects: 247
Study 22119063 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 247
Study 19286598 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment arms from various clinical trials for acute stroke
Number of subjects: 0